Schott M, Minich W B, Willenberg H S, Papewalis C, Seissler J, Feldkamp J, Bergmann A, Scherbaum W A, Morgenthaler N G
Department of Endocrinology, Diabetes and Rheumatology, University Hospital Duesseldorf, Moorenstrasse 5, 40225 Duesseldorf, Germany.
Horm Metab Res. 2005 Dec;37(12):741-4. doi: 10.1055/s-2005-921099.
Recently, we demonstrated that higher levels of autoantibodies to the human TSH receptor (TBII) predict relapse of hyperthyroidism in Graves' disease (GD). The aim of this study was to extend this outcome prediction by dividing TBII into stimulating (TSAb) and blocking (TBAb) TSH receptor autoantibodies. Altogether, ninety patients (81 female, 9 male) were retrospectively analyzed; sixty-four patients (71 %) did not go into remission or relapsed, whereas twenty-six patients (29 %) went into remission (median follow-up: 17.5 months). TSAb and TBAb measurement was performed in a CHO cell bioassay with cAMP readout at the time of their first visit in our outpatient clinic (single point measurement in median 6.5 months after initial diagnosis). In the remission group, eighteen of twenty-six patients (69 %) were TSAb-positive, whereas fifty-three of sixty-four patients (83 %) were TSAb-positive in the relapse group (p = ns). The mean stimulation indices (SI) were 4.1 in the remission group and 12.9 in the relapse group, respectively (p = 0.015). By using a threshold of 10 SI, the specificity for relapse was 96.0 %, as only one in twenty patients with an SI above 10 went into remission during follow-up (PPV 95 %). Most TSAb-positive patients also had high levels of TBII. Neither group showed any difference with respect to blocking type autoantibodies, which were mostly negative in both groups. In summary, high TSAb levels are similar but not superior to TBII for predicting relapse in GD patients. In contrast, TBAb measurement does not add any valuable information in this context. In the clinical routine, TSAb/TBAb measurement may not play an important role for diagnosis or outcome prediction of GD, since sensitive 2 (nd) generation TBII assays are easier to perform and offer similar information to the clinician. Bioassays should be reserved for special clinical questions such as Graves' disease in pregnancy.
最近,我们证明,针对人促甲状腺激素受体的自身抗体(TBII)水平较高可预测格雷夫斯病(GD)甲亢的复发。本研究的目的是通过将TBII分为刺激性(TSAb)和阻断性(TBAb)促甲状腺激素受体自身抗体来扩展这一结果预测。总共对90例患者(81例女性,9例男性)进行了回顾性分析;64例患者(71%)未缓解或复发,而26例患者(29%)缓解(中位随访时间:17.5个月)。在我们门诊首次就诊时,采用cAMP读数的CHO细胞生物测定法进行TSAb和TBAb检测(初诊后中位6.5个月进行单点测量)。在缓解组中,26例患者中有18例(69%)TSAb呈阳性,而在复发组的64例患者中有53例(83%)TSAb呈阳性(p = 无显著性差异)。缓解组和复发组的平均刺激指数(SI)分别为4.1和12.9(p = 0.015)。使用10 SI的阈值,复发的特异性为96.0%,因为在随访期间,SI高于10的20例患者中只有1例缓解(阳性预测值95%)。大多数TSAb阳性患者的TBII水平也较高。两组在阻断型自身抗体方面均无差异,两组大多为阴性。总之,高TSAb水平在预测GD患者复发方面与TBII相似但并不优于TBII。相比之下,在这种情况下,TBAb检测并未提供任何有价值的信息。在临床常规中,TSAb/TBAb检测可能对GD的诊断或结果预测不起重要作用,因为敏感的第二代TBII检测更容易进行,并且能为临床医生提供类似的信息。生物测定应保留用于特殊的临床问题,如妊娠合并格雷夫斯病。